CardioACC Secures Angel Funding to Break Foreign Monopoly and Accelerate Domestic ICE Development

VCBeat (WeChat: vcbeat) learned at the earliest opportunity that,CARDIOACC(abbreviated as“CARDIOACC”) announced the completion ofYuanBio Venture CapitalExclusively Invested ByAngel RoundFinancing, funds will be usedTeam Building and Advancement of R&D for Intracardiac Echocardiography (ICE) Products。KaichengCapital served as the financial advisor and will continue to be responsible for subsequent financing rounds.

Founded in October 2021, CARDIOACC is committed to becoming a global leader in cardiovascular interventional imaging and therapeutic technology. Leveraging the profound technical expertise of its core founding team and the relentless efforts of its R&D department, the company has achieved rapid progress and now possessesOver 20 Core Invention Patents, and preliminarily completedUltrasound Console, ICE Catheter, Electromagnetic Positioning, Imaging Algorithmthe development of key hardware and software product technologies.

As clinical demands for precision in cardiac catheterization interventions increase, interventional cardiologists require higher-resolution imaging and navigation tools for surgical procedures.

ICE catheter imaging, as an emerging interventional imaging technology, provides real-time, intuitive, and high-resolution anatomical information. This includes identification of cardiac structures, real-time intracardiac tracking of catheter position, and effective detection of procedural complications (such as pericardial effusion and thrombus formation), thereby enhancing the safety and efficacy of procedures. It is commonly applied in electrophysiology (including atrial fibrillation ablation, supraventricular tachycardia treatment, and pacemaker implantation) and structural heart disease interventions (including valve replacement and repair, hypertrophic cardiomyopathy ablation, and left atrial appendage closure).

Compared with conventional transthoracic echocardiography (TTE), intracardiac echocardiography (ICE) provides superior image clarity. In contrast to traditional transesophageal echocardiography (TEE), ICE does not require general anesthesia or transesophageal probe insertion, effectively avoiding esophageal-related injuries and complications, thereby enhancing patient experience and delivering health economic value.

However, the current ICE market in China is entirely monopolized by foreign companies, with no domestically launched products available. The exorbitant prices impose a significant burden on patients' families and the national medical insurance system.

CARDIOACC is dedicated to the concurrent development of 2D and 4D intracardiac echocardiography, aiming to provide safer and more cost-effective intraoperative imaging solutions for cardiac surgeries to patients worldwide.

Regarding this financing,Dr. Zhou Xinhuan, Founder of CARDIOACC“It stated: ‘Intracardiac echocardiography (ICE), as a crucial guidance tool for current cardiac interventional procedures, holds substantial potential commercial value and market opportunity. Since its inception, CARDIOACC has focused on mastering core bottleneck technologies in this field. By integrating the most advanced ICE imaging techniques available today, the company has rapidly advanced its projects while ensuring that key clinical performance parameters of its products meet or exceed those of leading international counterparts. Furthermore, CARDIOACC is establishing an ICE-based closed-loop commercial ecosystem to build a comprehensive platform for the diagnosis and treatment of heart diseases and to continuously drive innovation in medical devices for intracardiac surgeries.’”

Ban Bo, Partner at YuanBio Venture CapitalIt stated: “Intracardiac echocardiography (ICE) is essentially standard equipment for transseptal puncture and electrophysiology procedures abroad, with significant application potential in structural heart disease and left atrial appendage closure. In China, however, substantial technical barriers involving ultrasound probes, structural design, catheter manufacturing, and algorithms have prevented domestic manufacturers from achieving breakthroughs, leaving Johnson & Johnson as the dominant player. The founding team of CARDIOACC possesses extensive technical expertise in this field and is poised to break the import monopoly on 2D ICE, achieve the first domestic breakthrough in 4D ICE, rival international giants, and become the leading Chinese manufacturer. Furthermore, integrating intracardiac echocardiography with mapping and ablation technologies is expected to reshape the competitive landscape of the electrophysiology sector, creating substantial value for clinical practice and society.”

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector, headquartered in Suzhou BioBAY with a global reach. To date, it has invested in over 140 outstanding companies in the life and health sectors, covering four key areas: innovative drug development, medical devices, in vitro diagnostics (IVD) and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 16 of its portfolio companies listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a team of world-class scientific advisors, YuanBio Venture Capital possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, the firm is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

WinX Capital is a leading investment bank in China’s healthcare sector. Headquartered in Beijing and Shanghai, it serves over 3,000 active institutional investors and industrial groups. From 2020 to 2022, WinX Capital was consecutively recognized by Qimingpian & Xinsheng Chuangfu as “Top 2 Best Financial Advisors in Healthcare (2021–2022),” “Top 4 Best Financial Advisory Firms in Healthcare (2020),” “Top 10 Best Financial Advisors – Active List (2021),” “Top 6 Best Financial Advisors – Comprehensive List (Mid-2022),” and “Top 7 Best Financial Advisors – Active List (Mid-2022).” It was also named among the “Top 5 Most Promising New-Type Investment Banks in China (WISE 2020/2021)” by 36Kr and ranked among the “Top 5 Healthcare Financial Advisors of the Year” at VCBeat’s 2022 “Pengcheng Awards.”